Methods
Cancer
CANCER
The trial was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Clinical Practice. The trial was approved by the institutional review board of each institution (Severance Hospital: 4-2020-0386; Seoul National University Hospital: H-2101-017-1186; Samsung Medical Center: SMC 2020-08-078; National Cancer Center: NCC2021-0069; National University Cancer Institute: 2020/01198). Written informed consent was obtained from all participants before study enrollment. Patients did not receive any compensation for their participation. The trial was registered under the name “Olaparib Maintenance With Pembrolizumab & Bevacizumab in 